临床试验/NCT02129179

NCT02129179已完成1 期

The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure

Papworth Hospital NHS Foundation Trust1 个研究点分布在 1 个国家目标入组 10 人开始时间: 2014年6月最近更新: 2018年4月5日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Papworth Hospital NHS Foundation Trust
入组人数: 10
试验地点: 1
主要终点: Change in Pulmonary Vascular Resistance with Glucagon-Like Peptide-1

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study aims to assess the effect of glucagon-like peptide-1 on cardiac output and transpulmonary gradient in patients undergoing right heart catheterisation for clinical reasons.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Basic Science
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Age over 18
•Able to give informed consent
•On the waiting list for heart transplant
•Left Ventricular Dysfunction awaiting catheterisation

排除标准

•Nicorandil, glibenclamide, Dipeptidyl Peptidase-4 inhibitor, Glucagon-Like Peptide-1 receptor agonist or insulin
•Women of child bearing age and breast feeding women
•Cardiac pacemaker or other implanted metallic device
•Unable to give informed consent

研究组 & 干预措施

GLP-1

Experimental

干预措施: Glucagon-Like Peptide 1 (Drug)

结局指标

主要结局

Change in Pulmonary Vascular Resistance with Glucagon-Like Peptide-1

时间窗: 30 minutes

次要结局

未报告次要终点

研究者

发起方

Papworth Hospital NHS Foundation Trust

申办方类型

Other Gov

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

已完成

4 期

Cardiovascular Effects of GLP-1 Receptor ActivationObesityPreDiabetes

NCT03101930Vanderbilt University Medical Center329

已完成

2 期

Modulation of Human Myocardial Metabolism by GLP-1 Dose ResponseHealthyType 2 Diabetes Mellitus

NCT01607450Indiana University33

已完成

1 期

The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)Diabetes Mellitus, Type 2

NCT01449019Ludwig-Maximilians - University of Munich24

进行中（未招募）

1 期

A study to evaluate the effect of a licensed drug to lower blood glucose, liraglutide, on inflammation in patients with diabetic kidney disease.

EUCTR2012-005482-12-IEniversity College Dublin

已完成

不适用

Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in DiabetesObesityType 2 Diabetes

NCT01363609Amsterdam UMC, location VUmc50